Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064
This study is recruiting at 15 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Bipolar I Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 10 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alkermes, Inc.
- Last updated on ClinicalTrials.gov
- August 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Alkermes Investigator Site · Dothan, AL
Arkansas · 1
- Alkermes Investigator Site · Little Rock, AR
California · 1
- Alkermes Investigator Site · Stanford, CA
District of Columbia · 1
- Alkermes Investigator Site · Washington D.C., DC
Florida · 1
- Alkermes Investigator Site · Miami Lakes, FL
Georgia · 1
- Alkermes Investigator Site · Decatur, GA
Illinois · 1
- Alkermes Investigator Site · Chicago, IL
Indiana · 1
- Alkermes Investigator Site · Indianapolis, IN
Missouri · 1
- Alkermes Investigator Site · Saint Charles, MO
Nebraska · 1
- Alkermes Investigator Site · Lincoln, NE
New York · 1
- Alkermes Investigator Site · New York, NY
Ohio · 2
- Alkermes Investigator Site · Cincinnati, OH
- Alkermes Investigator Site · West Chester, OH
Virginia · 1
- Alkermes Investigational Site · Richmond, VA
Washington · 1
- Alkermes Investigator Site · Everett, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.